Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2023 | Genocea Biosciences, Inc. Went Out of Business | CI |
2023 | Liquidation Plan Approved for Genocea Biosciences, Inc. | CI |
Business Summary
Number of employees: 74
Sales per Business
USD in Million | 2020 | Weight | 2021 | Weight | Delta |
---|---|---|---|---|---|
Cancer Immunotherapies
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +20.75% |
Sales per region
USD in Million | 2020 | Weight | 2021 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +20.75% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 52 | 07-02-28 | |
Girish Aakalu
PRN | Corporate Officer/Principal | - | 18-12-09 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 14-09-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 58,783,503 | 58,783,503 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Genocea Biosciences, Inc.
Cambridge Discovery Park 100 Acorn Park Drive
02140, Cambridge
+617 876 8191
http://www.genocea.comSector
1st Jan change | Capi. | |
---|---|---|
0.00% | 58 | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+45.26% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- GNCAQ Stock
- Company Genocea Biosciences, Inc.